{"id":67644,"date":"2026-06-08T14:44:44","date_gmt":"2026-06-08T06:44:44","guid":{"rendered":"https:\/\/flcube.com\/?p=67644"},"modified":"2026-06-08T14:44:45","modified_gmt":"2026-06-08T06:44:45","slug":"sciwind-biosciences-unveils-superior-weight-loss-data-for-ecnoglutide-vs-semaglutide-at-ada-2026-first-camp-biased-glp-1-agonist-shows-35-greater-efficacy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67644","title":{"rendered":"Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 \u2013 First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sciwind Biosciences Co., Ltd.<\/strong> presented groundbreaking head-to-head data from the <strong>SLIMMER-UP-SWITCH<\/strong> study comparing <strong>ecnoglutide<\/strong> against <strong>semaglutide<\/strong> at the <strong>2026 American Diabetes Association (ADA) Scientific Sessions<\/strong>. The interim analysis revealed that ecnoglutide, the world&#8217;s first approved <strong>cAMP-biased GLP-1 receptor agonist<\/strong>, demonstrated significantly superior weight loss efficacy across all primary endpoints, potentially reshaping the competitive landscape in the $100B+ GLP-1 market.<\/p>\n\n\n\n<h2 id=\"h-study-design-amp-key-efficacy-results\" class=\"wp-block-heading\">Study Design &amp; Key Efficacy Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Ecnoglutide<\/th><th>Semaglutide<\/th><th>Relative Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Body Weight Reduction (20 weeks)<\/strong><\/td><td>-18.2%<\/td><td>-13.5%<\/td><td><strong>35% greater<\/strong><\/td><\/tr><tr><td><strong>Waist Circumference Reduction<\/strong><\/td><td>-15.3 cm<\/td><td>-12.7 cm<\/td><td><strong>20% greater<\/strong><\/td><\/tr><tr><td><strong>Patients Achieving \u226510% Weight Loss<\/strong><\/td><td>78%<\/td><td>41%<\/td><td><strong>Nearly double<\/strong><\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Head-to-head, randomized, active-controlled<\/td><td><\/td><td>N=1,200 patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-innovation\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Classification:<\/strong> First <strong>cAMP-biased GLP-1 receptor agonist<\/strong> \u2013 selectively activates cAMP pathway while minimizing \u03b2-arrestin recruitment<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Enhanced metabolic effects with potentially improved gastrointestinal tolerability profile<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> Approved in China (January 2026) as first-in-class therapy<\/li>\n\n\n\n<li><strong>Commercial Partnership:<\/strong> Global collaboration with <strong>Pfizer<\/strong> (February 2026) for worldwide development and commercialization<\/li>\n\n\n\n<li><strong>Dosing Regimen:<\/strong> Once-weekly subcutaneous injection with optimized pharmacokinetic profile<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-implications-amp-competitive-dynamics\" class=\"wp-block-heading\">Market Implications &amp; Competitive Dynamics<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GLP-1 Market Context:<\/strong> Global GLP-1 market projected to exceed $100B by 2030, currently dominated by semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly)<\/li>\n\n\n\n<li><strong>Pfizer&#8217;s Strategic Position:<\/strong> Entry into premium weight management segment through Sciwind partnership, challenging established players<\/li>\n\n\n\n<li><strong>Pricing Expectations:<\/strong> Premium pricing anticipated (15-20% above current GLP-1 standards) justified by superior efficacy data<\/li>\n\n\n\n<li><strong>China Launch Impact:<\/strong> Early market access in world&#8217;s largest diabetes population provides real-world evidence advantage<\/li>\n\n\n\n<li><strong>Investor Sentiment:<\/strong> Sciwind valuation expected to increase significantly following ADA presentation; Pfizer partnership validates global potential<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-pipeline-expansion-amp-future-indications\" class=\"wp-block-heading\">Pipeline Expansion &amp; Future Indications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ongoing Studies:<\/strong> Phase III trials in type 2 diabetes, NASH, and cardiovascular risk reduction<\/li>\n\n\n\n<li><strong>Combination Therapies:<\/strong> Investigational protocols with SGLT2 inhibitors and amylin analogs underway<\/li>\n\n\n\n<li><strong>Oral Formulation:<\/strong> Preclinical development of oral ecnoglutide expected to enter Phase I by Q1 2027<\/li>\n\n\n\n<li><strong>Biomarker Strategy:<\/strong> Patient stratification based on GLP-1 receptor polymorphism may optimize treatment response<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory approvals, and commercial expectations for ecnoglutide. Actual results may differ due to final study outcomes, regulatory decisions, competitive responses, and market adoption dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sciwind Biosciences Co., Ltd. presented groundbreaking head-to-head data from the SLIMMER-UP-SWITCH study comparing ecnoglutide against&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,17,822],"class_list":["post-67644","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-clinical-trial-results","tag-sciwind-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 \u2013 First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sciwind Biosciences Co., Ltd. presented groundbreaking head-to-head data from the SLIMMER-UP-SWITCH study comparing ecnoglutide against semaglutide at the 2026 American Diabetes Association (ADA) Scientific Sessions. The interim analysis revealed that ecnoglutide, the world&#039;s first approved cAMP-biased GLP-1 receptor agonist, demonstrated significantly superior weight loss efficacy across all primary endpoints, potentially reshaping the competitive landscape in the $100B+ GLP-1 market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67644\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 \u2013 First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy\" \/>\n<meta property=\"og:description\" content=\"Sciwind Biosciences Co., Ltd. presented groundbreaking head-to-head data from the SLIMMER-UP-SWITCH study comparing ecnoglutide against semaglutide at the 2026 American Diabetes Association (ADA) Scientific Sessions. The interim analysis revealed that ecnoglutide, the world&#039;s first approved cAMP-biased GLP-1 receptor agonist, demonstrated significantly superior weight loss efficacy across all primary endpoints, potentially reshaping the competitive landscape in the $100B+ GLP-1 market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67644\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-08T06:44:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-08T06:44:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67644#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67644\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 \u2013 First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy\",\"datePublished\":\"2026-06-08T06:44:44+00:00\",\"dateModified\":\"2026-06-08T06:44:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67644\"},\"wordCount\":364,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"Clinical trial results\",\"Sciwind Biosciences\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67644#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67644\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67644\",\"name\":\"Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 \u2013 First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-08T06:44:44+00:00\",\"dateModified\":\"2026-06-08T06:44:45+00:00\",\"description\":\"Sciwind Biosciences Co., Ltd. presented groundbreaking head-to-head data from the SLIMMER-UP-SWITCH study comparing ecnoglutide against semaglutide at the 2026 American Diabetes Association (ADA) Scientific Sessions. The interim analysis revealed that ecnoglutide, the world's first approved cAMP-biased GLP-1 receptor agonist, demonstrated significantly superior weight loss efficacy across all primary endpoints, potentially reshaping the competitive landscape in the $100B+ GLP-1 market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67644#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67644\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67644#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 \u2013 First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 \u2013 First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy - Insight, China&#039;s Pharmaceutical Industry","description":"Sciwind Biosciences Co., Ltd. presented groundbreaking head-to-head data from the SLIMMER-UP-SWITCH study comparing ecnoglutide against semaglutide at the 2026 American Diabetes Association (ADA) Scientific Sessions. The interim analysis revealed that ecnoglutide, the world's first approved cAMP-biased GLP-1 receptor agonist, demonstrated significantly superior weight loss efficacy across all primary endpoints, potentially reshaping the competitive landscape in the $100B+ GLP-1 market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67644","og_locale":"en_US","og_type":"article","og_title":"Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 \u2013 First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy","og_description":"Sciwind Biosciences Co., Ltd. presented groundbreaking head-to-head data from the SLIMMER-UP-SWITCH study comparing ecnoglutide against semaglutide at the 2026 American Diabetes Association (ADA) Scientific Sessions. The interim analysis revealed that ecnoglutide, the world's first approved cAMP-biased GLP-1 receptor agonist, demonstrated significantly superior weight loss efficacy across all primary endpoints, potentially reshaping the competitive landscape in the $100B+ GLP-1 market.","og_url":"https:\/\/flcube.com\/?p=67644","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-08T06:44:44+00:00","article_modified_time":"2026-06-08T06:44:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67644#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67644"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 \u2013 First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy","datePublished":"2026-06-08T06:44:44+00:00","dateModified":"2026-06-08T06:44:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67644"},"wordCount":364,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","Clinical trial results","Sciwind Biosciences"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67644#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67644","url":"https:\/\/flcube.com\/?p=67644","name":"Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 \u2013 First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-08T06:44:44+00:00","dateModified":"2026-06-08T06:44:45+00:00","description":"Sciwind Biosciences Co., Ltd. presented groundbreaking head-to-head data from the SLIMMER-UP-SWITCH study comparing ecnoglutide against semaglutide at the 2026 American Diabetes Association (ADA) Scientific Sessions. The interim analysis revealed that ecnoglutide, the world's first approved cAMP-biased GLP-1 receptor agonist, demonstrated significantly superior weight loss efficacy across all primary endpoints, potentially reshaping the competitive landscape in the $100B+ GLP-1 market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67644#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67644"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67644#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 \u2013 First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67644"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67644\/revisions"}],"predecessor-version":[{"id":67645,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67644\/revisions\/67645"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}